Monday, June 1, 2015

BRIEF-Transgene announces positive new results with TG4010 immunotherapy

<span id="midArticle_start"/> Transgene SA :

<span id="midArticle_0"/>* Announces positive new results from phase IIb time trialwith TG4010 immunotherapy in non-small cell lung cancer

<span id="midArticle_1"/> <span class="first-article-divide"/>* Says results have been presented at American Society ofClinical Oncology (ASCO) Annual Meeting in Chicago

<span id="midArticle_2"/> <span class="second-article-divide"/>* Data confirms strength of previously reported improvementsin progression-free survival (PFS) and overall survival (OS)

<span id="midArticle_3"/> <span class="third-article-divide"/>* TG4010 has improved response rate and longer duration ofresponse and activity in patients with low PD-L1 expressingtumors, particularly in patients with non-squamous tumorsSource text for Eikon: Further company coverage: (Gdynia Newsroom)

<span id="midArticle_4"/>


via Smart Health Shop Forum http://ift.tt/1FOoKQs

No comments: